Results 111 to 120 of about 15,844 (160)

Pathological characteristics and HER2 status of gastric cancer in Chinese high-incidence area. [PDF]

Medicine (Baltimore)
Wang H, Gao J, Li X, Chen Z, Ma L, Yan W, Zhang P, Wu X.   +7 more
europepmc   +1 more source

Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2 [PDF]

core   +1 more source

Mesenchymal stem cell-derived exosomes improve vascular remodeling by inhibiting EGFR/ErbB2 heterodimerization in hypoxic pulmonary hypertension. [PDF]

Sci Rep
Chen YX, Deng ZH, She XW, Gao X, Wei XY, Zhang GX, Qian JX.   +6 more
europepmc   +1 more source

The impact of HER2 low positivity in hormone receptor-positive, HER2-negative breast cancer treated with neoadjuvant chemotherapy. [PDF]

Cancer Biomark
Ersoy M.
europepmc   +1 more source

Influence of Peptide-Based Chelator Sequences on HER2-Targeting Radiopeptide. [PDF]

J Pept Sci
Gupta S, Kumar M, Repaka KM, Das A, Kengar AA, Satpati D.   +5 more
europepmc   +1 more source

Neoadjuvant twelve weekly paclitaxel-carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer. [PDF]

Breast Cancer Res Treat
Leshem Y, Golomb I, Zubkov A, Bar Y, Strulov Shachar S, Lerner S, Keren-Khadmy N, Sonnenblick A.   +7 more
europepmc   +1 more source

Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report. [PDF]

Thorac Cancer
Nishihara M, Shinno Y, Masui Y, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Ohe Y.   +10 more
europepmc   +1 more source

CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis. [PDF]

Target Oncol
Park D, Varda M, Yeremian S, Hwang A, Huang C.   +4 more
europepmc   +1 more source

Real-World Outcomes With Inetetamab-Based Regimens for HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Analysis in China. [PDF]

Cancer Control
Zheng F, Zhang J, Zhou D, Ren G, Qiang L, Wang T, Pan F, Shan C, Xia C, Yang F, Wang H, Liu G, Wang J, Hua R, Du X, Zhang B, Li H.   +16 more
europepmc   +1 more source

PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma. [PDF]

Cell Oncol (Dordr)
Qian R, Guo Y, Hu X, Ling J, Geng H, Ye Q, Zhang L, Zhan S, Liao L, Ge Y, Zheng Q, Cao Y.   +11 more
europepmc   +1 more source